FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With Del(5q)
Recurrent Childhood Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: azacitidine
Other: laboratory biomarker analysis

First Posted Date: 2010-03-10

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01083706

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Not Applicable

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Chronic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Noncontiguous Stage II Grade 2 Follicular Lymphoma
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Noncontiguous Stage II Adult Burkitt Lymphoma
Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma

Interventions: Drug: plerixafor
Biological: filgrastim
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2010-02-26

Last Posted Date: 2017-06-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01076270

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Spouses/Partners Expressing Their Thoughts After Transplant

Not Applicable

Completed

Conditions: Cancer
Hematopoietic Stem Cell Transplantation

Interventions: Behavioral: Emotional expression

First Posted Date: 2010-02-03

Last Posted Date: 2010-02-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 122

Registration Number: NCT01061801

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Blastic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: fludarabine phosphate
Drug: busulfan
Biological: anti-thymocyte globulin
Drug: tacrolimus
Drug: methotrexate
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2010-01-26

Last Posted Date: 2016-05-06

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 23

Registration Number: NCT01056614

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Health SMART (Stress Management and Relaxation Training)

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Cognitive Behavioral Stress Management (CBSM)

First Posted Date: 2010-01-13

Last Posted Date: 2012-03-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01048528

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome
Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia With Multilineage Dysplasia
Acute Undifferentiated Leukemia
Recurrent Follicular Lymphoma
T Lymphoblastic Lymphoma
Acute Erythroid Leukemia in Remission
Acute Myeloid Leukemia With FLT3/ITD Mutation
Ph+ ALL
Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1

Interventions: Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-12-09

Last Posted Date: 2023-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 46

Registration Number: NCT01028716

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Recurrent Childhood Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Plasma Cell Leukemia
Progression of Multiple Myeloma or Plasma Cell Leukemia
Recurrent Adult Non-Hodgkin Lymphoma
Recurrent Childhood Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Childhood Hodgkin Lymphoma
t(14;16)

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2009-11-05

Last Posted Date: 2019-06-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01008462

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Conditions: Melanoma (Skin)

First Posted Date: 2009-11-01

Last Posted Date: 2010-08-06

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01005537

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Adult Diffuse Large B-Cell Lymphoma
B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
T-Cell Non-Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bortezomib
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Rituximab
Drug: Vorinostat

First Posted Date: 2009-10-09

Last Posted Date: 2020-03-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00992446

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Refractory Cytopenia With Multilineage Dysplasia
Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts
Secondary Acute Myeloid Leukemia

Interventions: Biological: Pretargeted Radioimmunotherapy
Drug: Cyclosporine
Drug: Mycophenolate Mofetil
Radiation: Total-Body Irradiation
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Fludarabine Phosphate
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-10-02

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 17

Registration Number: NCT00988715

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy